Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for cancer treatment

A composition and cancer technology, applied in the field of therapeutic compositions for treating cancer, can solve problems such as limited efficacy and not very favorable clinical benefits

Inactive Publication Date: 2011-01-19
生物医学工程应用医药研究中心有限公司 +1
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical experiments show that the efficacy of IFN-α in the treatment of tumors is very limited, so the clinical benefit is not very favorable compared with the side effects, so its application in oncology is very limited at present

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for cancer treatment
  • Pharmaceutical composition for cancer treatment
  • Pharmaceutical composition for cancer treatment

Examples

Experimental program
Comparison scheme
Effect test

example

[0147] Delayed tumor growth in mice by combined administration of a 4-1BB receptor agonist ligand and type I interferon

[0148] I. Materials and methods

[0149] 1.1 Cell culture

[0150] Initially, the MC38 line from James Mulé's laboratory was supplemented with 10% v / v heat-inactivated fetal bovine serum (GIBCO), 50 μg / mL 2-mercaptoethanol, 100 U / mL penicillin, and 100 μg / mL chain Cultured in vitro in RPMI1640 medium (GIBCO). Cells were attached so they were detached from culture flasks (GREINER) by incubating for 5 minutes at room temperature using trypsin solution (GIBCO). After the cells were washed, they were isolated for culture or resuspended in saline serum for injection. The number of cells was determined by microscopy in a Neubauer chamber.

[0151] 1.2 Inoculation of tumor cells

[0152] 5x10 5 MC38 tumor cells were injected intradermally through an insulin syringe with a 28G needle, and were inoculated into experimental animals by a subcutaneous route s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to therapeutic compositions for the treatment of cancer and, more specifically, compositions containing an agonist ligand for receptor 4-1BB and a type-1 interferon, the simultaneous or sequential delivery of which results in a synergic antitumour effect in relation to the individual delivery of any of the components. The invention also relates to the therapeutic uses of the combinations of the invention for the treatment of cancer. The invention further relates to polynucleotides that code for compounds, vectors and cells containing same, as well as to the use thereof for the treatment of cancer.

Description

technical field [0001] The present invention relates to therapeutic compositions useful in the treatment of cancer, and more particularly to compositions comprising an agonist ligand for the receptor 4-1BB and a type I interferon. Background technique [0002] Currently, common medical treatments for cancer, such as chemotherapy, surgery, radiation therapy, and cell therapy, have imposed significant limitations on the efficacy and toxicity of said treatments. So far, these strategies have met with varying degrees of success, depending on the type of cancer, the patient's general health, the stage of the disease at diagnosis, and more. [0003] It is known in the art that the immune system plays a key role in the pathogenesis of various cancers. Cancer progression is thought to be due to failures in the immune response that allow cancer to develop. Possible strategies for the treatment of cancer include stimulating the immune system so that it specifically attacks tumor cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K38/21C07K16/28A61K35/12A61K35/76
CPCC07K16/2878A61K39/39541A61K38/212A61P35/00A61P37/04A61P43/00A61K2300/00A61K38/215A61K39/395C07K14/56C07K14/565C07K14/70503C07K14/7156C07K16/249
Inventor 伊格纳西奥哈维尔·梅莱罗·贝尔梅霍胡安·杜布罗特·阿门达里斯桑德拉·埃尔瓦斯·斯塔布斯阿涅丝洛朗斯·勒邦
Owner 生物医学工程应用医药研究中心有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com